Janmejay Singh

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri et al. · EBioMedicine · 2022 · 74 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months

Guruprasad R. Medigeshi, Gaurav Batra, Deepika Rathna Murugesan et al. · EBioMedicine · 2022 · 58 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Vaccine · 2022 · 33 citations

Veterinary Medicine, Immunology, Pediatrics +15

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Human Vaccines & Immunotherapeutics · 2023 · 32 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination

Suman R. Das, Janmejay Singh, Heena Shaman et al. · Nature Communications · 2022 · 23 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17